我院2005-2008年非小细胞肺癌化疗用药进展调研

Investigation on the trend of chemotherapeutics for NSCLC during the period of 2005-2008 in our hospital

目的:调查我院非小细胞肺癌患者化疗用药的进展情况。方法:回顾性调查我院2005-2008年164例非小细胞肺癌患者的化疗用药情况,分析我院治疗非小细胞肺癌的化疗用药进展情况。结果:我院非小细胞肺癌患者所有化疗药与卡铂联用的占30.20%,与顺铂联用的占59.73%。与卡铂联用的所有化疗药中,多西他赛占46.67%,吉西他滨占13.33%,紫杉醇占15.56%;与顺铂联用的所有化疗药中,多西他赛占41.57%,吉西他滨占32.58%,紫杉醇占3.37%。164例患者所用化疗药中,长春瑞滨13例、多西他赛65例、吉西他滨39例、培美曲塞二钠15例、紫杉醇11例。2005-2008年,长春瑞滨和紫杉醇用量呈逐年降低趋势;多西他赛用量基本平稳;吉西他滨用量2005-2007年呈逐年下降趋势,2008年用药情况有所回升;培美曲塞二钠用量逐年上升。结论:我院非小细胞肺癌患者的化疗用药基本是以多西他赛、吉西他滨、培美曲塞二钠、长春瑞滨、紫杉醇与顺铂、卡铂的联合用药为主;多西他赛和紫杉醇多与卡铂联用,吉西他滨多与顺铂联用。紫杉醇和长春瑞滨用量逐年下降,培美曲塞二钠用量逐年上升。

Objective： To investigate the usage and trend of chemotherapeutics for non-small-cell lung cancer （NSCLC） in PLA general hospital. Methods： The records of chemotherapy regimens for 164 advanced NSCLC patients during 2005-2008 were retrospectively investigated, and the development and trend of chemotherapeutic drugs were analyzed. Results： The combination chemotherapy regimens for advanced NSCLC in the hospital were mostly based on cisplatin （59.73%） and carboplatin （30.20%）. Among the anti-cancer drugs combined with carboplatin, docetaxel accounted for 46.67%, gemcitabine for 13.33%, and paclitaxel for 15.56%. Among the anti-cancer drugs combined with cisplatin, docetaxel accounted for 41.57%, gemcitabine for 32.58%, and paclitaxel for 3.37%. In the 164 advanced NSCLC patients, 65 cases took docetaxel,,39 cases took gemcitabine, 15 cases took pemetrexed, 13 cases took vinorelbine, and 11 cases took paclitaxel. The use of vinorebine and paclitaxel descended year by year from 2005 to 2008, the use of docetaxel were basically stable during this period, the application of pemetrexed increased year by year from 2005 to 2008, whereas the use of gemcitabine decreased from 2005 to 2007 but increased in 2008. Conclusion： The chemotherapy regimens for advanced NSCLC in our hospital were mostly the combined therapy of platinum （cisplatin or carboplatin） with docetaxel, gemcitabine, pemetrexed, vinorebine, or paclitaxel. Docetaxel and paclitaxel usually combined with carboplatin, gemcitabine usually combined with cisplatin. The annual dosage of paclitaxel and vinorebine decreased and that of pemetrexed increased gradually.